ACLX · CIK 1786205

What Arcellx, Inc. told the SEC could break it.

1 self-disclosed vulnerability, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.

A limited set so far, we surface every cited disclosure we’ve extracted for ACLX. More may follow as additional filings are processed.

In its own words

What could break it.

Supplier concentration

Third-party reliance for viral-vector manufacture/release testing, apheresis logistics, and product packaging/storage/distribution (CAR-T supply chain)medium
Arcellx's autologous CAR-T candidates (anito-cel, ARC-T) depend on a complex outsourced manufacturing and logistics chain: it relies on third parties to manufacture and release-test viral vectors and product candidates for clinical use, on third parties for patient apheresis material logistics, and on third parties to package, label, store and distribute its products. Viral-vector capacity and individualized apheresis/cell-processing logistics are notoriously constrained for cell therapies; a disruption at a key supplier could delay clinical development or commercial supply (it plans to leverage its Kite collaboration for commercial manufacturing). A concentrated, specialized CAR-T supply-chain dependence; suppliers unnamed → register risk.
“We currently rely on third parties for the manufacture and release testing of viral vectors and product candidates for clinical testing. We also currently rely on third parties for patient apheresis material logistics, as well as to package, label, store and distribute our product candidates.”
SEC filing →As of 2026

The hidden graph

Who it depends on, and who depends on it.

Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.

Its customers

Kite Pharma (Gilead Sciences, Inc.)
“The Company partnered anito-cel with Kite Pharma, Inc., a Gilead company (Kite)”
Cited →

In the MyPRIA app, this is checked against the companies you actually own.

← World Watch

What could break it.

Supplier concentration

Third-party reliance for viral-vector manufacture/release testing, apheresis logistics, and product packaging/storage/distribution (CAR-T supply chain)medium
Arcellx's autologous CAR-T candidates (anito-cel, ARC-T) depend on a complex outsourced manufacturing and logistics chain: it relies on third parties to manufacture and release-test viral vectors and product candidates for clinical use, on third parties for patient apheresis material logistics, and on third parties to package, label, store and distribute its products. Viral-vector capacity and individualized apheresis/cell-processing logistics are notoriously constrained for cell therapies; a disruption at a key supplier could delay clinical development or commercial supply (it plans to leverage its Kite collaboration for commercial manufacturing). A concentrated, specialized CAR-T supply-chain dependence; suppliers unnamed → register risk.
“We currently rely on third parties for the manufacture and release testing of viral vectors and product candidates for clinical testing. We also currently rely on third parties for patient apheresis material logistics, as well as to package, label, store and distribute our product candidates.”
SEC filing →As of 2026